Eli Lilly’s oral drug orforglipron (36 mg) resulted in an average weight loss of 12.4 kg
August 8, 2025
Source: drugdu
87
On August 7, Eli Lilly announced positive top-line results from the Phase 3 ATTAIN-1 clinical study. In ATTAIN-1, orforglipron achieved its primary endpoint, demonstrating significantly greater weight loss compared to placebo. At week 72, the highest dose (36 mg) of orforglipron achieved an average weight loss of 12.4 kg. These positive results are expected to bolster market confidence in Eli Lilly's weight loss strategy, boost its valuation, and strengthen its position in future market competition, attracting greater investor attention.
https://www.zhihuiya.com/news/info_10392.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
